MK 1966
Alternative Names: MK-1966Latest Information Update: 28 Jul 2019
At a glance
- Originator Merck & Co
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators; Interleukin 10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 08 Jan 2018 Merck terminates phase I trial in Haematological malignancies (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT02731742)
- 01 Jun 2016 Phase-I clinical trials in Haematological malignancies (Combination therapy; Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02731742)